Ira Turner
Neurology · Plainview, NYNPI 1306822929
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $456,347 of the $596,812 with a category attached, or 76.5%. 28 manufacturers reported payments, led by AbbVie at 39.0% of the total. Reporting peaked in 2021 at $208,880 and has fallen 99.9% since, to $183 in 2023. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 972 payments — averaging $614.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$233K
- Lilly USA, LLC$87K
- Amgen$86K
- Teva Pharmaceuticals USA, Inc.$68K
- Lundbeck LLC$40K
- Biohaven Pharmaceuticals, Inc.$29K
- plus $55K from 22 others
Across 26 payments — averaging $2627.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$22K
- Amgen$19K
- AbbVie$13K
- Novartis$5K
- Biohaven Pharmaceuticals, Inc.$4K
- Teva Pharmaceuticals USA, Inc.$4K
- plus $940 from 1 others
What the payments were for
- Consulting fees$77,73813%
- Speaking & faculty fees$456,34776%
- Grants$2,5880%
- Travel & lodging$37,2236%
- Food & beverage$22,6814%
- Education$2360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 387 | $232,979 |
| Lilly USA, LLC | 171 | $86,805 |
| Amgen | 105 | $85,769 |
| Teva Pharmaceuticals USA, Inc. | 91 | $67,658 |
| Lundbeck LLC | 52 | $39,699 |
| Biohaven Pharmaceuticals, Inc. | 42 | $29,309 |
| Impel Pharmaceuticals Inc. | 15 | $26,257 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $13,716 |
| Promius Pharma LLC | 7 | $4,958 |
| Biodelivery Sciences International, Inc. | 2 | $3,750 |
| Novartis | 16 | $2,735 |
| Currax Pharmaceuticals LLC | 6 | $1,584 |
| Biogen | 2 | $257 |
| EMD Serono, Inc. | 4 | $252 |
| AstraZeneca | 8 | $237 |
| Supernus Pharmaceuticals, Inc. | 9 | $159 |
| Avanir Pharmaceuticals, Inc. | 6 | $141 |
| Upsher-smith Laboratories LLC | 6 | $130 |
| Pfizer | 5 | $117 |
| Genentech USA, Inc. | 5 | $80 |
| Merz Pharmaceuticals, LLC | 2 | $77 |
| MDD US Operations, LLC | 3 | $42 |
| SK Life Science, Inc. | 1 | $25 |
| Zyla Life Sciences, Inc. | 1 | $19 |
| Medtronic | 1 | $15 |
| Abbott | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$119,164
- BOTOX$105,490
- AIMOVIG$81,596
- AJOVY$66,379
- EMGALITY$44,767
- NURTEC ODT$41,791
- VYEPTI$39,112
- Trudhesa$26,170
- REYVOW$16,350
- ZEMBRACE SYMTOUCH$4,800
- ELYXYB - CELECOXIB$3,750
- QULIPTA$3,261
- ONZETRA XSAIL$1,500
- MAYZENT$330
- Vumerity$132
- Rebif$110
How this compares
$596,812 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Plainview
- Stephen NewmanPlainview$489K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.